Literature DB >> 17311703

Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.

Xiyong Liu1, Bingsen Zhou, Lijun Xue, Frank Yen, Peiguo Chu, Frank Un, Yun Yen.   

Abstract

BACKGROUND: Ribonucleoside diphosphate reductase plays a key role in converting ribonucleoside diphosphate to 2'-deoxyribonucleoside diphosphate, which is necessary for DNA repair and replication. To determine if human ribonucleotide reductase small subunit M2 (hRRM2) and p53-dependent human ribonucleotide reductase small subunit R2 (p53R2) play roles on invasion ability of cancer cells, the gene transferring technique was used to construct stable hRRM2 and p53R2 overexpression transfectants. Increase of hRRM2 dramatically enhanced the cell migration in KB and PC-3 cells, but p53R2 overexpression reduced cellular invasion potential to 50% and 40% in KB and PC-3 cells, respectively. Furthermore, hRRM2 enhanced cancer cells to induce the cell migration of Human Umbilical Vein Endothelial Cells, but p53R2 reduced this ability in transfectants. PATIENTS AND METHODS: To further determine the role of human ribonucleotide reductase subunits on cancer metastasis, a tissue array, including 59 primary and 49 metastatic colon adenocarcinoma samples, was used. Immunohistochemistry was used to evaluate the relationship between human ribonucleotide reductase subunits and metastasis.
RESULTS: Univariate and multivariate analysis revealed that p53R2 is negatively related to the metastasis of colon adenocarcinoma samples (odds ratio, 0.23; P < 0.05); hRRM2 increases the risk of metastasis in colon cancer, but did not show significantly. Thus, opposing regulation of hRRM2 and p53R2 in invasion potential might play a critical role in determining the invasion and metastasis phenotype in cancer cells.
CONCLUSION: The expression level of ribonucleotide reductase small subunits could serve as biomarkers to predict the malignancy potential of human cancers in the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17311703     DOI: 10.3816/CCC.2007.n.007

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


  25 in total

1.  p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer.

Authors:  Nan-Yung Hsu; Jeng-Yuan Wu; Xiyong Liu; Yun Yen; Chih-Yi Chen; Ming-Chih Chou; Huei Lee; Ya-Wen Cheng
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

2.  Structural basis on the dityrosyl-diiron radical cluster and the functional differences of human ribonucleotide reductase small subunits hp53R2 and hRRM2.

Authors:  Bingsen Zhou; Leila Su; Yate-Ching Yuan; Frank Un; Norby Wang; Madhukar Patel; Bixin Xi; Shuya Hu; Yun Yen
Journal:  Mol Cancer Ther       Date:  2010-05-18       Impact factor: 6.261

3.  p53R2 overexpression in cervical cancer promotes AKT signaling and EMT, and is correlated with tumor progression, metastasis and poor prognosis.

Authors:  Chao Jiang; Rui Xu; Xiao-Xing Li; Yan-Yan Wang; Wen-Qian Liang; Ju-Deng Zeng; Shan-Shan Zhang; Xiao-Yi Xu; Yang Yang; Mei-Yin Zhang; Hui-Yun Wang; X F Steven Zheng
Journal:  Cell Cycle       Date:  2017-08-25       Impact factor: 4.534

Review 4.  Current progress of siRNA/shRNA therapeutics in clinical trials.

Authors:  John C Burnett; John J Rossi; Katrin Tiemann
Journal:  Biotechnol J       Date:  2011-07-11       Impact factor: 4.677

5.  A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.

Authors:  Bingsen Zhou; Leila Su; Shuya Hu; Weidong Hu; M L Richard Yip; Jun Wu; Shikha Gaur; D Lynne Smith; Yate-Ching Yuan; Timothy W Synold; David Horne; Yun Yen
Journal:  Cancer Res       Date:  2013-09-26       Impact factor: 12.701

6.  p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest.

Authors:  Keqiang Zhang; Jun Wu; Xiwei Wu; Xiaochen Wang; Yan Wang; Ning Zhou; Mei-ling Kuo; Xiyong Liu; Bingsen Zhou; Lufen Chang; David Ann; Yun Yen
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

7.  Ribonucleotide reductase metallocofactor: assembly, maintenance and inhibition.

Authors:  Caiguo Zhang; Guoqi Liu; Mingxia Huang
Journal:  Front Biol (Beijing)       Date:  2014-01-02

8.  Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis.

Authors:  Keqiang Zhang; Shuya Hu; Jun Wu; Linling Chen; Jianming Lu; Xiaochen Wang; Xiyong Liu; Bingsen Zhou; Yun Yen
Journal:  Mol Cancer       Date:  2009-02-28       Impact factor: 27.401

9.  Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy.

Authors:  Sanath R Wijerathna; Md Faiz Ahmad; Hai Xu; James W Fairman; Andrew Zhang; Prem Singh Kaushal; Qun Wan; Jianying Kiser; Chris G Dealwis
Journal:  Pharmaceuticals (Basel)       Date:  2011-10-13

10.  Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.

Authors:  Xiyong Liu; Hang Zhang; Lily Lai; Xiaochen Wang; Sofia Loera; Lijun Xue; Huiyin He; Keqiang Zhang; Shuya Hu; Yasheng Huang; Rebecca A Nelson; Bingsen Zhou; Lun Zhou; Peiguo Chu; Suzhan Zhang; Shu Zheng; Yun Yen
Journal:  Clin Sci (Lond)       Date:  2013-05       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.